Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1)

Autor:	Prasant Mohanty, Radim Nemecek, Razelle Kurzrock, Lucjan Wyrwicz, Tomasz Sarosiek, Mike Stecher, Tamas Hickish, John Simard, Judit Kocsis, Thierry André, Qian Wu, Charles A. Dinarello
Rok vydání:	2017
Předmět:	Oncology Interleukin 1a medicine.medical_specialty Interleukin 1 receptor antagonist business.industry Colorectal cancer Internal medicine medicine Endogeny Hematology business medicine.disease
Zdroj:	Annals of Oncology. 28:iii98-iii99
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx261.280
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e1d4a4a72af6224036aa05a985c8c0c1 https://doi.org/10.1093/annonc/mdx261.280 Zobrazit plný text záznamu